Evidence map›Paper›PMID 34938297›Full record

ArticleFrontiers in immunology2021

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.

Lieve Brochez, Vibeke Kruse, Dirk Schadendorf, Alexander J Muller, George C Prendergast

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lieve BrochezDepartment of Dermatology, University Hospital Ghent and Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Vibeke KruseDepartment of Medical Oncology, University Hospital Ghent and Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Dirk SchadendorfDepartment of Dermatology and Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.
Alexander J MullerLankenau Institute for Medical Research, Wynnewood, PA, United States.
George C PrendergastLankenau Institute for Medical Research, Wynnewood, PA, United States.

Funding

IDO Inhibitors for Combinatorial Cancer TherapyR01CA109542 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2005 to 2015
$2.0M
IDO2 Targeting in Pancreatic CancerR01CA191191 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2015 to 2019
$2.0M
IDO2 Targeting for pancreatic cancer treatmentR21CA159337 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2011 to 2012
$401k
NCI NIH HHS R01 CA109542NCI NIH HHS R01 CA191191NCI NIH HHS R21 CA159337
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ImmunotherapyAnimalsAntineoplastic AgentsEnzyme InhibitorsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseMolecular Targeted TherapyNeoplasmsSignal TransductionTryptophan OxygenaseTumor EscapeTumor MicroenvironmentAntineoplastic AgentsEnzyme InhibitorsIDO1 protein, humanIDO2 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseTryptophan Oxygenasecancer immunologyIDOimmunometabolismimmunotherapyTDO

Identifiers

PMID34938297
PMCPMC8686161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.